IO Biotech updates investor presentation for Jefferies Healthcare Conference

Rhea-AI Filing Summary

IO Biotech, Inc. announced that it will participate in the Jefferies Global Healthcare Conference beginning on November 18, 2025. In connection with this event, the company prepared an updated corporate investor presentation that it plans to use at the conference and in meetings with investors.

The updated investor presentation, referred to as the Investor Deck, was posted to the company’s website on November 18, 2025 and is also provided as an exhibit to this report. The company notes that this material is being furnished rather than filed under U.S. securities laws.

false 0001865494 0001865494 2025-11-18 2025-11-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 18, 2025

IO BIOTECH, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware		001-41008		87-0909276
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Ole Maaløes Vej 3

DK-2200 Copenhagen N

Denmark

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: +45 7070 2980

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		IOBT		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Beginning on November 18, 2025, IO Biotech, Inc., a Delaware corporation (the “Company”) will participate in the Jefferies Global Healthcare Conference (the “Conference”). The Company has updated the corporate presentation that it intends to use at the Conference and in meetings with investors, a copy of which was posted to the Company’s website on November 18, 2025 (the “Investor Deck”).

A copy of the Investor Deck is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information contained in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description
99.1		IO Biotech, Inc., Investor Deck, dated as of November 18, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IO BIOTECH, INC.
Date: November 18, 2025				By:		/s/ Mai-Britt Zocca, Ph.D.
				Name:		Mai-Britt Zocca, Ph.D.
				Title:		Chief Executive Officer

FAQ

What did IO Biotech, Inc. (IOBT) announce in this 8-K?

IO Biotech, Inc. disclosed that it will participate in the Jefferies Global Healthcare Conference starting on November 18, 2025 and has prepared an updated investor presentation for use at the event and in investor meetings.

What is the Investor Deck mentioned by IO Biotech (IOBT)?

The Investor Deck is an updated corporate presentation that IO Biotech intends to use at the Jefferies Global Healthcare Conference and in investor meetings, and it was posted to the company’s website on November 18, 2025.

Where can investors access IO Biotech’s updated investor presentation?

Investors can access IO Biotech’s updated Investor Deck on the company’s website and as Exhibit 99.1 to this report.

Is IO Biotech’s Investor Deck considered filed or furnished under securities laws?

The company states that the information in the report, including the Investor Deck attached as Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934.

Who signed the report on behalf of IO Biotech, Inc. (IOBT)?

The report was signed on behalf of IO Biotech, Inc. by Mai-Britt Zocca, Ph.D., the company’s Chief Executive Officer.